ALBPS.PA Biophytis EURONEXT down 21.87% intraday 11 Mar 2026: watch volume

Intraday trading in Europe is focused on ALBPS.PA stock after Biophytis (ALBPS.PA) fell 21.87% to €0.03 on EURONEXT on 11 Mar 2026 on heavy volume. The move followed a large trade block that pushed volume to 15,688,719 shares versus an average of 786,640. We examine market drivers, technical levels, liquidity, and near-term scenarios for active traders and investors.

Intraday price action and volume: ALBPS.PA stock

Biophytis (ALBPS.PA) dropped 21.87% intraday to €0.03555 on EURONEXT on 11 Mar 2026, with a session low of €0.03300 and high of €0.03740.

Trading volume spiked to 15,688,719 shares, nearly 20.00x the average volume of 786,640, which signals a liquidity-driven move that active traders should monitor.

Fundamentals snapshot: ALBPS.PA stock financials and risks

Biophytis is a clinical-stage biotech in Healthcare and Biotech, with market cap near €1,043,062.00 and 23,230,769 shares outstanding. The company reports EPS -0.34 and PE -0.13, reflecting negative earnings and early-stage risk.

Key balance metrics show cash per share €0.06, current ratio 0.35, and enterprise value €7,608,062.00, highlighting funding and solvency risks that matter for investors weighing ALBPS.PA stock long term.

Technical levels and indicators: ALBPS.PA stock technicals

Short-term indicators show oversold conditions: RSI 32.65 and CCI -138.75, with Bollinger bands at €0.04–€0.06, suggesting a volatility squeeze. The 50-day average is €0.06 and 200-day average is €0.11, both well above the current price.

Support is near the intraday low €0.03300 and resistance near €0.05 and then €0.10; traders should use tight risk controls given wide swings and a low market cap.

Meyka grade and analyst context: ALBPS.PA stock

Meyka AI rates ALBPS.PA with a score out of 100: the platform assigns a B+ (71.30) and suggests BUY based on cross-checks versus S&P 500 and sector comparisons. This grade factors in benchmark, sector performance, financial growth, key metrics, and analyst consensus.

Third-party company rating dated 10 Mar 2026 shows a C rating with a Sell recommendation in some models, underlining mixed views between quantitative models and our proprietary grade.

Catalysts and sector context: ALBPS.PA stock news and risks

Short-term catalysts include clinical updates and partnership announcements tied to Sarconeos (BIO101) and Macuneos (BIO201). Any progress on trials or licensing could rapidly change sentiment for ALBPS.PA stock.

Healthcare sector peers show more stable metrics (average PE 30.19) and higher liquidity, so Biophytis carries sector-specific clinical trial risk and relative illiquidity that increase volatility.

Trading strategy and price targets: ALBPS.PA stock

For intraday and swing traders, we flag a near-term tactical resistance at €0.05 and a stop below €0.032 to limit downside on volatile volume spikes. A conservative 3-month price target is €0.10 for recovery scenarios.

Longer-term model targets are more variable; position sizing and cash runway analysis are essential given negative cash flow and small market cap.

Final Thoughts

ALBPS.PA stock is trading as one of today’s most active names on EURONEXT, down 21.87% to €0.03555 on 11 Mar 2026 with volume 15,688,719. The drop highlights liquidity-driven volatility rather than a single clear fundamental revision. Meyka AI’s forecast model projects a 12‑month scenario of €2.97827, implying roughly +8,277.70% versus the current price, but this is a model projection and not a guarantee. Use short stops and small position sizes for intraday trades, and watch clinical readouts or funding news as primary catalysts. For reference, see the company site and profile: Biophytis website and Biophytis LinkedIn. For live order flow and quotes use our platform: ALBPS.PA on Meyka. Meyka AI is an AI-powered market analysis platform providing real-time signals and grades to guide active trading decisions. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.